The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Carboplatin (CBDCA), S-1 and concurrent thoracic radiotherapy (TRT) for elderly patients with locally advanced non-small cell lung cancer (NSCLC): A phase I study.
 
Seiji Niho
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Lilly (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Lilly Japan
Research Funding - AstraZeneca (Inst); Bayer (Inst); Lilly Japan (Inst); Novartis (Inst); Takeda (Inst)
 
Keisuke Kirita
No Relationships to Disclose
 
Shigeki Umemura
Honoraria - Boehringer Ingelheim
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); MSD (Inst)
 
Shingo Matsumoto
Honoraria - Novartis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hironobu Ohmatsu
No Relationships to Disclose
 
Koichi Goto
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Taiho Pharmaceutical
Research Funding - Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; OxOnc; Pfizer; Riken Genesis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
 
Yukio Hosomi
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
 
Hiroshi Tanaka
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroaki Okamoto
Research Funding - AstraZeneca Japan (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Keiji Nihei
No Relationships to Disclose
 
Tetsuo Akimoto
No Relationships to Disclose
 
Yuichiro Ohe
Employment - Chugai Pharma (I)
Stock and Other Ownership Interests - Ono Pharmaceutical (I)
Honoraria - AstraZeneca Japan; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Lilly Japan; MSD; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Kyorin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - AstraZeneca Japan